{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:43Z","timestamp":1793155783695,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40265-021-01476-3","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T12:02:36Z","timestamp":1614859356000},"page":"483-494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Secukinumab: A Review in Psoriatic Arthritis"],"prefix":"10.1007","volume":"81","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"issue":"1","key":"1476_CR1","first-page":"S45","volume":"15","author":"S Hackett","year":"2020","unstructured":"Hackett S, Coates L. Psoriatic arthritis: an up to date overview. Indian J Rheumatol. 2020;15(1):S45-51.","journal-title":"Indian J Rheumatol."},{"issue":"Suppl. 1","key":"1476_CR2","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","volume":"59","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020;59(Suppl. 1):i37-46.","journal-title":"Rheumatology (Oxford)"},{"key":"1476_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108536","author":"A Toussi","year":"2020","unstructured":"Toussi A, Maverakis N, Le ST, et al. Updated therapies for the management of psoriatic arthritis. Clin Immunol. 2020. https:\/\/doi.org\/10.1016\/j.clim.2020.108536.","journal-title":"Clin Immunol."},{"key":"1476_CR4","first-page":"53","volume":"14","author":"MS Chimenti","year":"2020","unstructured":"Chimenti MS, D\u2019Antonio A, Conigliaro P, et al. An update for the clinician on biologics for the treatment of psoriatic arthritis. Biologics. 2020;14:53\u201375.","journal-title":"Biologics."},{"issue":"3","key":"1476_CR5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379\u201390.","journal-title":"Clin Rev Allergy Immunol."},{"key":"1476_CR6","unstructured":"Novartis. COSENTYX\u00ae (secukinumab) injection: US prescribing information. 2020. https:\/\/dailymed.nlm.nih.gov. Accessed 18 Jan 2021."},{"key":"1476_CR7","unstructured":"European Medicines Agency. Secukinumab (Cosentyx): EU summary of product characteristics. 2020. https:\/\/www.ema.europa.eu. Accessed 18 Jan 2021."},{"issue":"11","key":"1476_CR8","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-016-0602-3","volume":"76","author":"M Shirley","year":"2016","unstructured":"Shirley M, Scott LJ. Secukinumab: a review in psoriatic arthritis. Drugs. 2016;76(11):1135\u201345.","journal-title":"Drugs."},{"issue":"4","key":"1476_CR9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-015-0143-7","volume":"16","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP. Secukinumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2015;16(4):323\u201330.","journal-title":"Am J Clin Dermatol."},{"issue":"4","key":"1476_CR10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-019-01075-3","volume":"79","author":"HA Blair","year":"2019","unstructured":"Blair HA. Secukinumab: a review in ankylosing spondylitis. Drugs. 2019;79(4):433\u201343.","journal-title":"Drugs."},{"issue":"10","key":"1476_CR11","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40265-016-0598-8","volume":"76","author":"HA Blair","year":"2016","unstructured":"Blair HA, Dhillon S. Secukinumab: a review in ankylosing spondylitis. Drugs. 2016;76(10):1023\u201330.","journal-title":"Drugs."},{"issue":"14","key":"1476_CR12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med."},{"issue":"9999","key":"1476_CR13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346.","journal-title":"Lancet"},{"issue":"1","key":"1476_CR14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","volume":"20","author":"P Nash","year":"2018","unstructured":"Nash P, Mease PJ, McInnes IB, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018;20(1):47.","journal-title":"Arthritis Res Ther."},{"issue":"3","key":"1476_CR15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","volume":"6","author":"AJ Kivitz","year":"2019","unstructured":"Kivitz AJ, Nash P, Tahir H, et al. Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study. Rheumatol Ther. 2019;6(3):393\u2013407.","journal-title":"Rheumatol Ther."},{"issue":"6","key":"1476_CR16","first-page":"890","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease P, van der Heijde D, Landewe R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890\u20137.","journal-title":"Ann Rheum Dis."},{"key":"1476_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808","author":"X Baraliakos","year":"2020","unstructured":"Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2020. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218808.","journal-title":"Ann Rheum Dis."},{"key":"1476_CR18","doi-asserted-by":"crossref","unstructured":"D'Agostino M, Schett G, Lopez-Rdz A, et al. Secukinumab significantly decreased joint synovitis measured by power doppler ultrasonography in biologic-naive patients with active psoriatic arthritis: primary (12-week) results from a randomized, placebo-controlled phase III study [abstract no. 1361]. In: American College of Rheumatology Convergence. 2020.","DOI":"10.1093\/rheumatology\/keab247.182"},{"issue":"10235","key":"1476_CR19","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496\u2013505.","journal-title":"Lancet"},{"issue":"6","key":"1476_CR20","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/rheumatology\/kez420","volume":"59","author":"D van der Heijde","year":"2020","unstructured":"van der Heijde D, Mease PJ, Landewe RBM, et al. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology (Oxford). 2020;59(6):1325\u201334.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 2","key":"1476_CR21","first-page":"262","volume":"78","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Landewe RBM, Rahman P, et al. Subcutaneous secukinumab 300 mg and 150 mg provides sustained inhibition of radiographic progression in psoriatic arthritis over 2 years: results from the phase 3 FUTURE-5 trial [abstract no. LB0006]. Ann Rheum Dis. 2019;78(Suppl. 2):262.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"1476_CR22","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","volume":"56","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017;56(11):1993\u20132003.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1476_CR23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Mease PJ, Reimold AM, et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res. 2017;69(3):347\u201355.","journal-title":"Arthritis Care Res."},{"issue":"1","key":"1476_CR24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/acr2.11097","volume":"2","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study. ACR Open Rheumatol. 2020;2(1):18\u201325.","journal-title":"ACR Open Rheumatol."},{"key":"1476_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000723","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. 2018. https:\/\/doi.org\/10.1136\/rmdopen-2018-000723.","journal-title":"RMD Open."},{"issue":"Suppl. 2","key":"1476_CR26","first-page":"379","volume":"77","author":"P Nash","year":"2018","unstructured":"Nash P, McInnes IB, Rahman P, et al. Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year results from the phase 3 FUTURE 2 study [abstract no. THU0322]. Ann Rheum Dis. 2018;77(Suppl. 2):379.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"1476_CR27","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","volume":"2","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Mease PJ, Kivitz AJ, et al. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. Lancet Rheumatol. 2020;2(4):e227\u201335.","journal-title":"Lancet Rheumatol."},{"issue":"8","key":"1476_CR28","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/art.39685","volume":"68","author":"D van der Heijde","year":"2016","unstructured":"van der Heijde D, Landewe RB, Mease PJ, et al. Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheumatol. 2016;68(8):1914\u201321.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"1476_CR29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","volume":"76","author":"V Strand","year":"2017","unstructured":"Strand V, Mease P, Gossec L, et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis. 2017;76(1):203\u20137.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"1476_CR30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13075-018-1610-3","volume":"20","author":"IB McInnes","year":"2018","unstructured":"McInnes IB, Mease PJ, Schett G, et al. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthritis Res Ther. 2018;20(1):113.","journal-title":"Arthritis Res Ther."},{"issue":"10","key":"1476_CR31","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.23537","volume":"70","author":"LC Coates","year":"2018","unstructured":"Coates LC, Mease PJ, Gossec L, et al. Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res. 2018;70(10):1529\u201335.","journal-title":"Arthritis Care Res."},{"issue":"1","key":"1476_CR32","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-018-1773-y","volume":"20","author":"LC Coates","year":"2018","unstructured":"Coates LC, Gladman DD, Nash P, et al. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Res Ther. 2018;20(1):272.","journal-title":"Arthritis Res Ther."},{"issue":"4","key":"1476_CR33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2020.03.015","volume":"50","author":"LC Coates","year":"2020","unstructured":"Coates LC, Nash P, Kvien TK, et al. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. Semin Arthritis Rheum. 2020;50(4):709\u201318.","journal-title":"Semin Arthritis Rheum."},{"issue":"7","key":"1476_CR34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/14712598.2020.1761957","volume":"20","author":"MS Chimenti","year":"2020","unstructured":"Chimenti MS, Fonti GL, Conigliaro P, et al. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opin Biol Ther. 2020;20(7):813\u201321.","journal-title":"Expert Opin Biol Ther."},{"issue":"Suppl. 1","key":"1476_CR35","first-page":"1674","volume":"79","author":"PG Conaghan","year":"2020","unstructured":"Conaghan PG, Holdsworth E, Tian H, et al. Real world effectiveness of secukinumab in psoriatic arthritis: findings from a recent cross sectional survey of rheumatologists and patients in Europe [abstract no. AB0755]. Ann Rheum Dis. 2020;79(Suppl. 1):1674\u20135.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl. 2","key":"1476_CR36","first-page":"889","volume":"78","author":"U Kiltz","year":"2019","unstructured":"Kiltz U, Peterlik D, Winkelmann V, et al. AQUILA study in Germany\u2014real world data on secukinumab\u2019s effectiveness in psoriatic arthritis patients\u2014results from an interim analysis [abstract no. FRI0405]. Ann Rheum Dis. 2019;78(Suppl. 2):889\u201390.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl. 1","key":"1476_CR37","first-page":"1169","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Blachley T, Glynn M, et al. Secukinumab improves clinical and patient-reported outcomes at 6 months among patients with psoriatic arthritis in the US-based Corrona psoriatic arthritis\/spondyloarthritis (PsA\/SpA) registry [abstract no. SAT0429]. Ann Rheum Dis. 2020;79(Suppl. 1):1169.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl. 1","key":"1476_CR38","first-page":"722","volume":"79","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Marchesoni A, Balduzzi S, et al. Effectiveness and retention rate of secukinumab for psoriatic arthritis and axial spondyloarthritis: real-life data from the Italian LORHEN registry [abstract no. FRI0273]. Ann Rheum Dis. 2020;79(Suppl. 1):722\u20133.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl. 1","key":"1476_CR39","first-page":"730","volume":"79","author":"M Lorenzin","year":"2020","unstructured":"Lorenzin M, Carletto A, Foti R, et al. Effectiveness and safety of secukinumab in naive or TNF-inhibitors failure psoriatic arthritis patients in real life: a 24-months prospective multicenter study [abstract no. FRI0284]. Ann Rheum Dis. 2020;79(Suppl. 1):730.","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"1476_CR40","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40261-019-00856-8","volume":"39","author":"M Magrey","year":"2019","unstructured":"Magrey M, Bozyczko M, Wolin D, et al. Evaluation of the feasibility of a web-based survey to assess patient-reported symptom improvement and treatment satisfaction among patients with psoriatic arthritis receiving secukinumab. Clin Drug Investig. 2019;39(12):1205\u201312.","journal-title":"Clin Drug Investig."},{"issue":"Suppl. 2","key":"1476_CR41","first-page":"915","volume":"78","author":"LM Martin","year":"2019","unstructured":"Martin LM, Valero M, Emperiale V, et al. Real-world experience of secukinumab for psoriatic arthritis [abstract no. FRI0448]. Ann Rheum Dis. 2019;78(Suppl. 2):915.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl. 2","key":"1476_CR42","first-page":"611","volume":"78","author":"E Holdsworth","year":"2019","unstructured":"Holdsworth E, Booth N, Lobosco S, et al. Real world physician satisfaction with secukinumab in psoriatic arthritis and ankylosing spondylitis in Europe [abstract no. THU0635]. Ann Rheum Dis. 2019;78(Suppl. 2):611\u20132.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl. 2","key":"1476_CR43","first-page":"1814","volume":"78","author":"U Kiltz","year":"2019","unstructured":"Kiltz U, Peterlik D, Winkelmann V, et al. AQUILA study in Germany\u2014real world adherence and persistence of secukinumab treatment in ankylosing spondylitis and psoriatic arthritis patients\u2014an interim analysis [abstract no. AB0705]. Ann Rheum Dis. 2019;78(Suppl. 2):1814\u20135.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl. 1","key":"1476_CR44","first-page":"1169","volume":"79","author":"B Michelsen","year":"2020","unstructured":"Michelsen B, Georgiadis S, Giuseppe DI, D, , et al. Secukinumab effectiveness in 1543 patients with psoriatic arthritis treated in routine clinical practice in 13 European countries in the EuroSpA research collaboration network [abstract no. SAT0430]. Ann Rheum Dis. 2020;79(Suppl. 1):1169\u201371.","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"1476_CR45","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2217\/cer-2019-0023","volume":"8","author":"KR Oelke","year":"2019","unstructured":"Oelke KR, Chambenoit O, Majjhoo AQ, et al. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. J Comp Eff Res. 2019;8(8):607\u201322.","journal-title":"J Comp Eff Res."},{"key":"1476_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa710","author":"JG Letarouilly","year":"2020","unstructured":"Letarouilly JG, Flachaire B, Labadie C, et al. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison. Rheumatology (Oxford). 2020. https:\/\/doi.org\/10.1093\/rheumatology\/keaa710.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 1","key":"1476_CR47","first-page":"431","volume":"79","author":"U Lindstrom","year":"2020","unstructured":"Lindstrom U, Glintborg B, Giuseppe DDI, et al. Comparison of treatment retention of secukinumab and TNF-inhibitors in psoriatic arthritis. Observational data from a Nordic collaboration [abstract no. THU0394]. Ann Rheum Dis. 2020;79(Suppl. 1):431\u20132.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"1476_CR48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.","journal-title":"Arthritis Res Ther."},{"issue":"Suppl. 1","key":"1476_CR49","first-page":"722","volume":"79","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, McInnes I, Baraliakos X, et al. Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: updated pooled safety analysis [abstract no. FRI0272]. Ann Rheum Dis. 2020;79(Suppl. 1):722.","journal-title":"Ann Rheum Dis."},{"key":"1476_CR50","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3257","author":"BE Elewski","year":"2020","unstructured":"Elewski BE, Baddley JW, Deodhar AA, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol. 2020. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3257.","journal-title":"JAMA Dermatol."},{"issue":"4","key":"1476_CR51","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3899\/jrheum.190116","volume":"47","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Gladman DD, McInnes IB, et al. Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis. J Rheumatol. 2020;47(4):539\u201347.","journal-title":"J Rheumatol."},{"issue":"6","key":"1476_CR52","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"1476_CR53","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060\u201371.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"1476_CR54","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5\u201332.","journal-title":"Arthritis Rheumatol."},{"issue":"10235","key":"1476_CR55","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(20)30800-X","volume":"395","author":"ML Hetland","year":"2020","unstructured":"Hetland ML. Psoriatic arthritis: still room for improvement. Lancet. 2020;395(10235):1463\u20135.","journal-title":"Lancet"},{"issue":"11","key":"1476_CR56","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/cer-2018-0075","volume":"7","author":"IB McInnes","year":"2018","unstructured":"McInnes IB, Nash P, Ritchlin C, et al. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics\/apremilast: a network meta-analysis. J Comp Eff Res. 2018;7(11):1107\u201323.","journal-title":"J Comp Eff Res."},{"issue":"1","key":"1476_CR57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3899\/jrheum.180797","volume":"47","author":"A Mourad","year":"2020","unstructured":"Mourad A, Gniadecki R. Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and metaanalysis. J Rheumatol. 2020;47(1):59\u201365.","journal-title":"J Rheumatol."},{"issue":"4","key":"1476_CR58","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jbspin.2018.01.011","volume":"85","author":"T Reygaerts","year":"2018","unstructured":"Reygaerts T, Mitrovic S, Fautrel B, et al. Effect of biologics on fatigue in psoriatic arthritis: a systematic literature review with meta-analysis. Jt Bone Spine. 2018;85(4):405\u201310.","journal-title":"Jt Bone Spine."},{"issue":"3","key":"1476_CR59","first-page":"508","volume":"38","author":"N Simons","year":"2020","unstructured":"Simons N, Degboe Y, Barnetche T, et al. Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes. Clin Exp Rheumatol. 2020;38(3):508\u201315.","journal-title":"Clin Exp Rheumatol."},{"key":"1476_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0011-1","author":"V Strand","year":"2018","unstructured":"Strand V, Husni ME, Betts KA, et al. Network meta-analysis and cost per responder of targeted immunomodulators in the treatment of active psoriatic arthritis. BMC Rheumatology. 2018. https:\/\/doi.org\/10.1186\/s41927-018-0011-1.","journal-title":"BMC Rheumatology."},{"issue":"7","key":"1476_CR61","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2217\/cer-2018-0141","volume":"8","author":"V Strand","year":"2019","unstructured":"Strand V, McInnes I, Mease P, et al. Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis. J Comp Eff Res. 2019;8(7):497\u2013510.","journal-title":"J Comp Eff Res."},{"issue":"6","key":"1476_CR62","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1007\/s12325-020-01352-8","volume":"37","author":"U Kiltz","year":"2020","unstructured":"Kiltz U, Sfikakis PP, Gaffney K, et al. Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: baseline data from SERENA study. Adv Ther. 2020;37(6):2865\u201383.","journal-title":"Adv Ther."},{"key":"1476_CR63","unstructured":"National Institute for Health and Care Excellence. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. 2017. http:\/\/www.nice.org.uk. Accessed 18 Jan 2021."},{"issue":"1","key":"1476_CR64","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40258-019-00523-1","volume":"18","author":"A Gandjour","year":"2020","unstructured":"Gandjour A, Ostwald DA. Cost effectiveness of secukinumab versus other biologics and apremilast in the treatment of active psoriatic arthritis in Germany. Appl Health Econ Health Policy. 2020;18(1):109\u201325.","journal-title":"Appl Health Econ Health Policy."},{"key":"1476_CR65","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vhri.2019.03.002","volume":"20","author":"E Aiello","year":"2019","unstructured":"Aiello E, Bianculli PM, Bhattacharyya D, et al. Cost-effectiveness of secukinumab versus other biologics in the treatment of psoriatic arthritis: an Argentinean perspective. Value Health Reg Issues. 2019;20:86\u201394.","journal-title":"Value Health Reg Issues."},{"issue":"1","key":"1476_CR66","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-018-1653-5","volume":"20","author":"E Kampylafka","year":"2018","unstructured":"Kampylafka E, d\u2019Oliveira I, Linz C, et al. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17a blockade with secukinumab: results from the prospective PSARTROS study. Arthritis Res Ther. 2018;20(1):153.","journal-title":"Arthritis Res Ther."}],"updated-by":[{"DOI":"10.1007\/s40265-021-01513-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01476-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01476-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01476-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T11:18:06Z","timestamp":1697973486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01476-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01476-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"2 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01513-1","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01513-1","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"H. A. Blair is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}